跳至主要内容
临床试验/NCT07463885
NCT07463885尚未招募不适用

Spontaneous Versus Controlled Mechanical Ventilation in Patients With Acute Hypoxemic Respiratory Failure: A Feasibility Study and Pilot Trial

Oslo University Hospital0 个研究点目标入组 80 人开始时间: 2026年9月1日最近更新:
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
80
主要终点
Recruitment Rate

研究概览

简要总结

Acute hypoxemic respiratory failure may progress to acute respiratory distress syndrome, a life-threatening condition that often requires mechanical ventilation. The optimal ventilation strategy in this patient population remains uncertain.

The SVALBARD trial is a feasibility and pilot study designed to compare spontaneous versus controlled mechanical ventilation in patients with acute hypoxemia respiratory failure.

The primary objective is to assess the feasibility of the study procedures and interventions, while also collecting descriptive data on key clinical variables to inform the design of a future randomized controlled trial.

详细描述

Acute hypoxemic respiratory failure is a condition that can progress to acute respiratory distress syndrome (ARDS), requiring invasive mechanical ventilation to support gas exchange and limit lung injury. ARDS guidelines recommend lung-protective ventilation strategies-specifically low tidal volumes and limited airway pressures-to reduce ventilator-induced lung injury. Observational studies, including the global LUNG SAFE project, have described the epidemiology and management of acute hypoxemic respiratory failure and ARDS. These studies report high mortality rates (global hospital mortality, 38.6%) associated with the severity of lung injury rather than strict fulfilment of ARDS criteria. They also reveal variability in the application of evidence-based ventilation strategies across institutions. This inconsistency highlights a barrier to progress: the lack of conclusive evidence guiding ventilation management in patients with acute hypoxemic respiratory failure.

One unresolved issue is the role of spontaneous breathing during mechanical ventilation. Observational studies suggest that allowing spontaneous effort may reduce need for sedation and increase ventilator-free days. In contrast, preclinical models indicate that spontaneous breathing in severe lung injury may worsen outcomes through mechanisms such as patient-ventilator asynchrony and regional overdistension. This contrast underscores the need to balance potential benefits against physiological risks in the absence of adequate trial data. ARDS guidelines do not provide clear recommendations on this issue due to limited evidence. Only one large RCT has compared controlled ventilation to spontaneous breathing modes, finding no difference in short-term outcomes and not assessing long-term endpoints such as cognitive impairment or quality of life.As a result, clinicians must choose between guideline-based controlled ventilation and approaches that incorporate spontaneous breathing, within the context of evolving sedation practices and recovery goals. Given the variability of acute hypoxemic respiratory failure and the current evidence gap, genuine uncertainty ('clinical equipoise') exists regarding the optimal ventilation strategy. This supports the need for well-designed RCTs to determine whether spontaneous ventilation offers clinical benefit or harm. A recent survey of Nordic clinicians showed support for such a trial in patients with moderately severe acute hypoxemic respiratory failure, underscoring the relevance of this research.

The SVALBARD study is a feasibility and pilot trial comparing spontaneous and controlled mechanical ventilation in patients with acute hypoxemic respiratory failure. The study will evaluate whether it is possible to recruit patients, apply the assigned ventilation strategies, and collect the required data in a reliable way.

In addition, the study will collect descriptive clinical data to better understand patient characteristics and outcomes. The results will be used to improve the design and planning of a future randomized controlled trial.

The trial will accrue 80 patients from eight different intensive care units, four in Norway and four in Denmark.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • We will include patients who fulfil all the following criteria:
  • Acutely admitted to the ICU
  • AND age ≥ 18 years
  • AND invasive mechanical ventilation via endotracheal tube or tracheostomy for less than 24 hours
  • AND moderate acute hypoxemic respiratory failure, defined as a PaO₂-FiO₂ ratio between 13.3-26.6 kPa (100-200 mmHg) with PEEP ≥ 5 cm H2O, based on arterial blood gas analysis obtained within 2 hours before randomisation.
  • AND new pulmonary infiltrate (uni- or bilateral) on chest x-ray or CT-scan obtained no more than 24 hours before randomisation.

排除标准

  • Previously randomised into the SVALBARD trial.
  • Informed consent following inclusion expected to be unobtainable
  • Patient under coercive measures
  • Withdrawal from active therapy or brain death deemed imminent.
  • Chronic hypercapnic respiratory failure defined as PaCO2 > 8 kPa (60 mm Hg) in the outpatient setting.
  • Listed for lung transplant.
  • Acute heart failure / acute myocardial infarction / cardiac arrest during or causing index ICU admission.
  • Use of home oxygen.
  • Chronic mechanical ventilation for any reason except for non-invasive mechanical ventilation (CPAP/BIPAP) used solely for sleep apnoea disorder.
  • Currently receiving ECMO therapy.
  • Burns >70 % total body surface.
  • Acute brain injury or stroke (any, including subarachnoid haemorrhage, SAH).
  • Intracranial hypertension.
  • Patients with planned repeat surgical interventions during current stay in ICU.

研究组 & 干预措施

Spontaneous ventilation

Experimental

Invasive mechanical ventilation in which the patient initiates some or all breaths, and the ventilator assists or supports those spontaneous efforts.

干预措施: Spontaneous Ventilation Strategy (Procedure)

Controlled ventilation

Active Comparator

Invasive mechanical ventilation in which all breaths are delivered by the ventilator, with no patient-initiated respiratory effort.

干预措施: Controlled Ventilation Strategy (Procedure)

结局指标

主要结局

Recruitment Rate

时间窗: 1 year from trial initiation

Proportion of eligible patients who are enrolled in the trial (primary feasibility outcome).

次要结局

  • Protocol Adherence(1 year from trial initiation)
  • Consent Rate(1 year from trial initiation)
  • Randomisation Rate(1 year from trial initiation)
  • Major Protocol Violations(1 year from trial initiation)
  • Retention Rate(1 year from trial initiation)
  • Time to Completion of Feasibility Study(Up to 1 year)
  • Proportion of Participants Achieving Therapeutic Target at 48 Hours(48 hours from randomisation)
  • Between-Group Difference in Therapeutic Target Attainment at 48 Hours(48 hours)
  • Proportion of Missing Therapeutic Target Data at 48 Hours(48 hours from randomisation)
  • Clinical: All-Cause Mortality at 30 Days(30 days)
  • Clinical: All-Cause Mortality at 90 Days(90 days)
  • Clinical: All-Cause Mortality at 180 Days(180 days)
  • Clinical: Clinical: Days Alive and Free of Life Support at 90 Days(90 days)
  • Clinical: Days Alive and Out of Hospital at 90 Days(90 days)
  • Clinical: Health-related quality of life (EQ-5D-5L Index Score)(180 days)
  • Clinical: Health-Related Quality of Life (EQ-5D Visual Analogue Scale Score)(180 days)
  • Clinical: Montreal Cognitive Assessment (MoCA) Score at 180 Days(180 days)
  • Clinical: Impact of Event Scale-6 (IES-6) Score at 180 Days(180 days)
  • Clinical: Modified Medical Research Council (mMRC) Dyspnea Scale Score at 180 Days(180 days)
  • Clinical: Chalder Fatigue Questionnaire (CFQ) Score at 180 Days(180 days)

研究者

发起方
Oslo University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jon Henrik Laake

Principal Investigator, MD, PhD

Oslo University Hospital

相似试验